To identify patients eligible for first line PARPi maintenance therapy, reflex tumour testing for BRCA1/2 pathogenic/likely pathogenic variants has been implemented for all patients diagnosed with advanced-stage high-grade epithelial ovarian cancer [12]. This evidence concerns the gene BRCA1 and neoplasm.